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Summary 
Mouse mammary tumor virus (MMTV) encodes a superantigen  (SAg) that promotes stable infection 
and virus transmission.  Upon subcutaneous MMTV injection,  infected B cells present SAg to 
SAg-reactive T cells leading to a strong local immune response in the draining lymph node (LN) 
that peaks after 6 d. We have used the reverse transcriptase inhibitor Y-azido-Y-deoxythymidine 
(AZT) to dissect in more detail the mechanism of SAg-dependent enhancement of MMTV infection 
in this system. Our data show that  no detectable B or T  cell response to SAg occurs in AZT 
pretreated mice. However, if AZT treatment is delayed 1-2 d after MMTV injection, a normal 
SAg-dependent local immune response is observed on day 6. Quantitation of viral DNA in draining 
LN of these infected mice indicates that a 4,000-fold increase in the absolute numbers of infected 
cells occurs between days 2 and 6 despite the presence of AZT. Furthermore MMTV DNA was 
found preferentially in surface IgG + B cells  of infected mice and was not detectable in SAg- 
reactive T  cells.  Collectively our data suggest that MMTV infection occurs preferentially in B 
cells without SAg involvement and is completed 1-2 d after virus challenge.  Subsequent amplifica- 
tion of MMTV infection between days 2 and 6 requires SAg expression and occurs in the absence 
of any further requirement for reverse transcription. We therefore conclude that clonal expansion of 
infected B cells via cognate interaction with SAg-reactive T cells is the predominant mechanism 
for increasing  the level of MMTV infection.  Since infected B cells display a memory (surface 
IgG +) phenotype, both clonal expansion and possibly longevity of the virus carrier cells may 
contribute to stable MMTV infection. 
S 
uperantigens (SAgs) are proteins of bacterial or viral orion 
that  bind  to  MHC  class  II  molecules  and  interact 
specifically  with TCR Vfl domains  (1).  Mouse mammary 
tumor virus (MMTV) is a milk-transmitted type B retrovirus 
that encodes a SAg in its 3' LTR (2, 3). After infection of 
mice by MMTV, T  lymphocytes react with the SAg mole- 
cule expressed on the surface of infected B cells,  leading to 
a local immune response (4, 5). This SAg-dependent immune 
reaction ultimately results in amplification of MMTV infec- 
tion and virus transmission  (5-8); however the precise sequence 
of events that follow MMTV infection have not been clarified. 
Here  we  use  the  reverse  transcriptase  inhibitor  Y-azido- 
Y-deoxythymidine (AZT) to identify an initial SAg-indepen- 
dent phase of MMTV penetration  and integration.  Subse- 
quent amplification of infection occurs primarily (if not ex- 
clusively) via clonal expansion of the initially infected B cells 
due to SAg-mediated cognate interaction  with  T  cells. 
Materials and Methods 
Mice and Injections.  Adult BALB/c mice were purchased from 
HO Harlan OLAC Ltd. (Bicester, UK). Mtv-7  + (Mls-la) congenic 
BALB/c (BALB.D2) mice were derived from breeding pairs origi- 
nally provided by H. Festenstein (London Hospital Medical Col- 
lege, London,  UK) (9). BALB/c mice were injected with either 
106 Mtv-7  + B cells or '~10  s MMTV (SW) virus particles in the 
footpad.  AZT  (Sigma Chemical  Co.,  St.  Louis, MO) was ad- 
ministered to mice in drinking  water (1 mg/ml). On the first day 
of treatment  AZT was also injected intraperitoneally  at a dose of 
3 mg (corresponding  to a daily dose of AZT taken up through 
drinking  water)  (10). 
Flow Microfluorometry  and Cell Sorting.  PBL were recovered  from 
samples of heparinized blood by centrifugation  on a cushion of 
Ficoll-Hypaque (Pharmacia LKB, Uppsala, Sweden). LN cells or 
PBL were labeled in a single step with direct FITC conjugates of 
either anti-Vfl6 (44.22.1) (11) or anti-Vf114 (14.2) (12) mAbs to- 
gether  with  anti-CD4-PE  (GK1.5) (Becton  Dickinson  &  Co., 
Mountain View, CA). B cells were detected with FITC labeled  rabbit 
F(ab)'2 anti-mouse Ig. All samples were analyzed using a FACScan  | 
and the Lysys II program (Becton Dickinson & Co.). For sorting, 
LN cells were stained either with FITC-labeled anti-Vfl6 and anti- 
CD4-PE or with biotinylated goat anti-mouse IgG (Caltag Labora- 
tories Inc., San Francisco, CA) followed by avidin PE plus FITC 
labeled rabbit F(ab)'2 anti-mouse Ig. Cells were sorted to a purity 
of >95% using  a FACStar Plus  |  (Becton Dickinson  & Co.). 
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after virus injection the local (popliteal  and paraaortic) LN were 
removed and DNA was isolated by digestion in 10 mM Tris-HC1, 
pH 8, 100 mM NaC1, 25 mM EDTA, pH 8, 0.5% SDS plus Pro- 
teinase K (100 pg/ml) at 52~  overnight. After purifcation the 
DNA  equivalent of 10  s cells  (,~0.5  /~g of DNA)  was  used  per 
PCR reaction. The oligonucleotides VJ84-VJ71 were used to am- 
plify all Mtvs endogenous to BALB/c mice (i.e., Mtv-6, 8, 9) as pre- 
viously described (4). The oligo RM53 (CTAGGAACAGGAAT- 
GAACTTC) together with VJ71 (4) was used to amplify specifically 
MMTV (SW)/Mtv-7 DNA. This PCR assay was performed and 
analyzed as for the quantitative assay described before (5). Quan- 
titative PCR analysis of MMTV (SW) infection normalized to en- 
dogenous Mtv loci has been described  in detail before (5).  Signal 
quantification was performed with a Phosphorimager SF (Molec- 
ular Dynamics Inc., Sunnyvale, CA) using MD ImageQuant soft- 
ware for data evaluation.  The MMTV (SW) DNA content was 
calculated  relative to the signal  derived from the Mtv-7 locus  as 
described previously. 
Results  and Discussion 
We have previously identified MMTV  (SW)  as an infec- 
tious homologue of the endogenous provirus Mtv-7, which 
encodes a SAg that primarily reacts with V36 + T  cells (13). 
Infection with MMTV (SW) leads to a SAg-dependent im- 
mune response, which amplifies viral infection (5). As shown 
in  Fig.  1  a  a  detectable  response  of SAg-reactive  VB6 + 
CD4 +  T  cells  was  first  observed  in  the  draining  LN  of 
BALB/c mice on day 3  after MMTV  (SW)  injection  into 
the footpad. This T  cell response was maximal between day 
4  and  6  and  preceded the B  cell response by •  1 d  (Fig.  1 
a) (4).  To correlate these kinetic data directly with viral in- 
fection we used a PCR-based assay specific for MMTV (SW) 
DNA sequences located in the LTRs (4). This sensitive assay 
indicated that newly synthesized viral DNA was first detect- 
able at day 2 after injection and increased thereafter (Fig.  2 
a). Furthermore, a quantitative PCR assay (5) showed max- 
imal MMTV (SW) infection at day 5 and 6 (data not shown). 
Thus the degree of MMTV  infection coincides temporally 
with  the  SAg-induced  immune  response. 
Since there are potentially multiple ways in which MMTV 
infection could be amplified and therefore different levels at 
which the MMTV SAg could act (14) we first assessed whether 
a  SAg-induced  immune  response can occur in  the  absence 
of reverse transcription. To this end we injected MMTV (SW) 
into the footpad of AZT pretreated BALB/c mice and ana- 
lyzed the draining LN 6 d later. As shown in Table 1 a specific 
increase of SAg-reactive V/~6 +CD4 +  T  cells  and  a  corre- 
sponding B cell increase was observed in the local LN of control 
mice upon exposure to MMTV (SW). These responses were 
not seen when MMTV (SW) was injected into AZT pretreated 
mice (Table 1). Analysis of the viral DNA present in these 
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Figure  1.  Kinetics  of the MMTV (SW) induced SAg response and its 
dependence  upon reverse  transcriptase  activity. (a) Kinetics of local B and 
T cell responses to SAg after injection of 'x,10  s MMTV (SW) particles. 
(b) Local  B and T cell responses to MMTV (SW) SAg (measured at day 
6) in mice treated with AZT at the indicated time points. (c) Effect of 
AZT on V/36  § CD4 + T  cell deletion in peripheral blood induced by 
MMTV (SW). (d) Dose response analysis of MMTV (SW) SAg induced 
local stimulation (4 d) and peripheral deletion (6 wk) of V/~6  + CD4 + 
T cells. 
Figure 2.  Effect  of AZT on MMTV (SW) infection. PCR was per- 
formed with MMTV (SW)/Mtv-7-specific  (a) or total Mw-specific (b) 
primers using DNA purified from the draining LN taken at the indicated 
time points after virus was injected into normal or AZT-treated  mice. (c) 
Mixing experiment to illustrate the sensitivity  of the MMTV (SW)/Mw- 
7-specific PCR. Lymphocytes  from Mtv-7- BALB/c (containing Mw 6, 
8, and 9) and Mtv-7  + congenic BALB.D2 (Mw 6, 7, 8, and 9) mice were 
mixed in various ratios before DNA purification. 
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Percent  CD4 T  cells expressing 
AZT  Stimulation  n  V36  V314  B cells 
x  10  ~ 
-  -  6  11.7  _+  0.6  10.6  +  0.8  1.1  _+  0.5 
+  -  6  12.0  _+  0.7  10.1  +  0.6  1.0  _+  0.7 
-  MMTV  (SW)  3  29.8  _+  4.4  8.0  +_  1.2  6.6  +_  4.5 
+  MMTV  (SW)  3  12.6  _+  0.7  10.0  _+  0.8  1.4  +_  0.2 
-  MW-7 (Mls-1)  3  33.9  _+  1.1  6.5  _+  0.5  6.3  +  2.2 
+  MW-7  (Mls-1)  3  33.0  _+  1.8  7.3  _+  0.2  5.4  _+  1.1 
BALB/c mice were treated with AZT starting 1 d before injection with either ~o10  s MMTV(SW) particles  or with 106 B cells from Mtv.7 congenic 
BALB.D2 mice. The immune response in the local  (popliteal and paraaortic) lymph nodes was assessed 6 d  after injection. Data are expressed  as 
mean  _+  SD of the indicated number of mice. 
AZT-treated  compared  with  nontreated  mice  (Fig.  2  a) 
confirming that MMTV reverse transcriptase was efficiently 
inhibited by AZT. These results indicate that a detectable local 
immune response induced by the MMTV (SW) SAg is strictly 
dependent  upon reverse  transcription. 
More definitive evidence that reverse transcription is a pre- 
requisite for MMTV (SW) SAg expression was obtained by 
monitoring  the kinetics of clonal deletion of VB6+CD4 + 
T cells in AZT-treated infected mice. We have shown previ- 
ously that  the local immune  response to MMTV  (SW) is 
followed by a progressive  deletion  of SAg-reactive V36 + 
CD4 + T cells in the peripheral blood (13). As shown in Fig. 
1 c this deletion does not occur in infected mice treated with 
AZT over a 6-wk period. Direct comparison ofMMTV (SW) 
titration curves for local expansion (measured at 4 d) and pe- 
ripheral deletion (measured at 6 wk) of V~6 +  CD4 + T cells 
after local infection indicates  that  the clonal deletion assay 
is ~ 1,000-fold more sensitive,  since 10  s virus particles induce 
detectable  deletion  whereas  10  s  particles  are  required  for 
significant expansion (Fig. I d). Based on these data we con- 
clude that functional SAg is unlikely to be present in the ma- 
ture virion before reverse transcription or to be expressed using 
the RNA genome, or a portion thereof (15),  as a template 
(16).  Rather it appears that SAg expression occurs de novo 
after integration  of the MMTV genome into the host ge- 
nome.  Thus,  viral entry and integration  most likely occur 
independently  of SAg activity. 
To rule out a nonspecific effect of AZT on the local im- 
mune response induced by MMTV SAg we injected B cells 
from an Mw-7 + mouse strain (BALB/D2) (9) into the foot- 
pad of congenic Mtv-7-  recipients (BALB/c). This induced 
a local response of V36 + CD4 + T cells comparable in mag- 
nitude to that  seen upon MMTV (SW) injection (13,  17) 
(Table 1). However, since Mtv-7 is an endogenous provirus, 
expression of its SAg does not require reverse transcription. 
As shown in  Table  1 the V36+CD4 + T  cell response  to 
MW-7 +  cells  was not affected by AZT pretreatment,  indi- 
cating that the local immune responses to MMTV SAgs are 
not  susceptible to nonspecific effects of AZT. 
After virus integration  and expression of functional SAg 
molecules, at least two mechanisms could account for the 
tAg-dependent  amplification of infection occurring during 
the local immune  response to MMTV.  Initial  infection of 
a few B cells (presumably without SAg involvement) followed 
by de novo expression of SAg and T  ceU proliferation could 
lead to activation of bystander B cells, for example via cytokine 
release. Preferential infection of these bystander cells (18-20) 
would then lead to amplification of MMTV infection.  An 
alternative (but not mutually exclusive)  mechanism would 
be that  infected B cells  are induced  to donally expand via 
cognate interaction with tAg-reactive T cells. As can be seen 
from Fig. I b, AZT exposure begun 1 d before or at the same 
time as MMTV (SW) injection prevented the local immune 
response, which was assessed in the LN 6 d later.  However, 
if AZT treatment is delayed 1-2 d after MMTV (SW) injec- 
tion, an immune response is observed that is comparable in 
magnitude to the control response without AZT treatment. 
These results indicate that MMTV reverse transcriptase ac- 
tivity is no longer required for the induction of an optimal 
SAg response 1-2 d after virus injection.  Since at this time 
point there are no significant T  or B cell responses (Fig.  1 
a), infection of activated bystander B cells is unlikely to rep- 
resent an important mechanism for further stimulation and/or 
maintainence of the SAg response. This conclusion is further 
strengthened by quantitative analysis of the degree of MMTV 
(SW) infection in these LN (Fig. 3). No MMTV (SW) DNA 
was detected in the local LN on day 6 when AZT treatment 
was begun 1 d before or at the time of MMTV (SW) injec- 
tion.  However, the levels  of MMTV (SW) infection were 
indistinguishable in control and treated animals when AZT 
was given 2 d or more after virus injection (Fig.  3). These 
data strongly suggest that the tAg-dependent amplification 
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AZT. Quantitative PCR. analysis of MMTV (SW) DNA content (relative 
to endogenous Mtv loci) on day 6 in the draining LN of infected BALB/c 
mice treated  with AZT at the indicated  time points. 
of MMTV (SW) infection observed after day 2 did not re- 
quire reverse transcriptase activity and was therefore limited 
to previously infected cells. 
Characterization of MMTV (SW) infected cells in LN at 
day 6 after virus injection confirmed our previous observa- 
tion that at this stage viral DNA was exclusively detected 
in B and not T  cells (5).  More detailed analyses indicated 
that MMTV (SW) carriers are phenotypically surface IgG + 
(Fig.  4) and large, activated B cells (5).  Besides  this B cell 
subset, only SAg-reactive T  cells were found to proliferate 
in the local LN (4, 5). However, since purified VB6 +  CD4 § 
T cells were not found to be detectably infected (Fig.  4), we 
would conclude that B cells (or a subset thereof) represent 
the primary target for MMTV infection. 
The absolute magnitude of the increase in MMTV (SW)- 
infected B cells in the draining LN under our experimental 
conditions can be estimated by assuming an average of four 
viral integrations per infected B cell.  (This estimate is based 
on our unpublished analysis of 20 B cell hybridomas derived 
by fusion of day 6 infected LN).  On day 2 after infection, 
the MMTV (SW) DNA signal is roughly equivalent to an 
artificial mixture of one Mtv-7 + (diploid) LN cell/104 Mtv-7- 
cells (see Fig.  2, a and c). Since these draining LN contain 
5  x  106 cells,  this corresponds to  '~250  infected cells.  By 
day 6  the relative MMTV (SW) DNA content is 20%  of 
the endogenous Mtv-7 + control (Fig.  3), corresponding to 
~106 infected cells in a draining LN containing 10  x  106 
total cells. This level of clonal expansion (~4,000-fold) would 
require at least 12 B cell divisions in 4 d or a doubling time 
of "~8 h.  Even shorter doubling times  (6-7  h)  have been 
reported for germinal center B cells (21). The fact that in- 
fected B  cells  are surface IgG + further suggests  that  they 
may constitute a pool of long-lived virus carriers (22,  23). 
Figure 4.  Phenotype  of MMTV (SW)  infected cells. At day 6 after 
virus injection  LN cells were sorted  into subsets according  to the indi- 
cated phenotypes. The anti-lgG antibody detects ,,o8% surface IgG + cells 
among total Ig + LN B calls in control mice. At day 6 after virus injec- 
tion "~12% of surface Ig + cells were found  to be surface IgG + . DNA 
isolation and the quantitative  PCR. assay was performed as described (5). 
Therefore, besides clonal expansion, longevity of infected B 
cells may ensure virus survival in the host and ultimately con- 
tribute to  the infection of mammary tissue. 
It is important to emphasize that the conclusions reached 
herein pertaining to the mechanism of SAg-mediated ampli- 
fication of MMTV infection in lymphocytes are based on a 
somewhat artificial  model in which adult mice are infected 
subcutaneously. It will therefore be important to assess the 
effects of SAg-mediated immune interactions during natural 
infection by milk-borne virus via the neonate gut mucosa. 
Despite this caveat, it seems very likely that the SAg-induced 
clonal expansion of infected B cells seen in adult mice is also 
important during natural infection since SAg-reactive T cells 
are required for MMTV  transmission (5-8). 
Finally the model system described here may prove useful 
in a more general context as a screening procedure for the 
efficiency of novel antiretroviral drugs. In this regard mon- 
itoring the SAg-dependent local immune response of V~6 + 
CD4 § T cells by flow microfluorometry represents a rapid, 
sensitive,  quantitative, and reproducible assay that depends 
strictly upon MMTV reverse transcriptase activity in vivo. 
Importantly, immunosuppressive properties of compounds 
under study can be dissociated from their true antiviral effects 
by parallel assessment of responses to infectious and endoge- 
nous MMTV SAgs. Such a system should complement other 
methods of screening antiretroviral drugs in vivo, for example 
the SCID-human mouse modal (24). 
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